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Context: Late-onset hypogonadism (LOH) has recently been defined as a syndrome inmiddle-aged
and elderly men reporting sexual symptoms in the presence of low T. The natural history of LOH,
especially its relationship to mortality, is currently unknown.
Objective: The aim of this study was to clarify the associations between LOH, low T, and sexual
symptoms with mortality in men.
Design, Setting, and Participants: Prospective data from the European Male Aging Study (EMAS) on
2599 community-dwellingmen aged 40–79 years in eight European countries was used for this study.
Main OutcomeMeasure(s):All-cause, cardiovascular, and cancer-relatedmortality was measured.
Results:One hundred forty-sevenmen died during amedian follow-up of 4.3 years. Fifty-fivemen
(2.1%)were identified as having LOH (31moderate and 24 severe). After adjusting for age, center,
body mass index (BMI), current smoking, and poor general health, compared with men without
LOH, those with severe LOH had a 5-fold [hazard ratio (HR) 5.5; 95% confidence interval (CI) 2.7,
11.4] higher risk of all-causemortality. Comparedwith eugonadalmen, themultivariable-adjusted
risk of mortality was 2-fold higher in those with T less than 8 nmol/L (irrespective of symptoms; HR
2.3; 95% CI 1.2, 4.2) and 3-fold higher in those with three sexual symptoms (irrespective of serum
T; compared with asymptomatic men; HR 3.2; 95% CI 1.8, 5.8). Similar risks were observed for
cardiovascular mortality.
Conclusions: Severe LOH is associatedwith substantially higher risks of all-cause and cardiovascular
mortality, to which both the level of T and the presence of sexual symptoms contribute indepen-
dently. Detecting low T inmen presentingwith sexual symptoms offers an opportunity to identify
a small subgroup of aging men at particularly high risk of dying. (J Clin Endocrinol Metab 99:
1357–1366, 2014)
Serum T levels gradually decline with age in men (1, 2).However, the clinical significance of this remains un-
clear and controversial (3). Recent guidelines have at-
tempted to establish a syndrome of late-onset hypogonad-
ism (LOH) as a clinical and biochemical state with
advancing age, characterized by typical symptoms and
low T (4). This concept, however, remains contentious (5)
because there is uncertainty about the clinical significance
of LOH in the absence of objective information on its
natural history and response to T replacement therapy (6).
To improve the specificity of the diagnosis, we have re-
cently proposed the minimum criteria for LOH based on
the simultaneous occurrence of three sexual symptoms
(decreased sexual interest and morning erections and erec-
tile dysfunction) and total T below 11 nmol/L and free T
below 220 pmol/L (7). Using these criteria, we have also
reported associations between LOH and a variety of end
organ deficits suggestive of androgen deficiency (8). How-
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ever, the clinical significance and the natural history of
LOH remain largely undefined.
Several studies have shown association of low T with
increased risk of all-cause and cardiovascular-related
mortality, although a recent meta-analysis of 12 commu-
nity-based studies have revealed considerable inconsis-
tency between individual studies (9). Whether low T is a
nonspecific risk marker of poor health (9, 10) or the as-
sociation is mediated by the effects of T deficiency on the
cardiovascular system (11) is currently unclear. Erectile
dysfunction (ED) is increasingly recognizedasanearlywarn-
ing signal of impending cardiovascular disease and a predic-
tor of excessive mortality (12–14). If our proposed criteria of
low T and sexual symptoms (including ED) identify a syn-
drome of symptomatic androgen deficiency (7, 8), it would
be important to determine whether LOH is also associated
with increased all-cause or cause-specific mortality.
Using longitudinal data from the European Male Aging
Study (EMAS), the primary aim of this study was to ex-
amine the association between LOH and mortality with
the secondary objective of estimating the relative contri-
butions of low T and sexual symptoms.
Materials and Methods
Subjects and study design
Subjects were recruited to participate in the EMAS, the details
of which, including study design and methodologies, have been
fully described (15). Briefly, an age-stratified probability sample
of 3369 men aged 40–79 years (mean  SD: 60  11 y) were
recruited from population registers in eight European centers
(Florence, Italy; Leuven, Belgium; Malmö, Sweden; Manchester,
United Kingdom; Santiago de Compostela, Spain; Lódz, Poland;
Szeged, Hungary; Tartu, Estonia). Subjects completed a postal
questionnaire and then attended a research clinic for detailed
clinical assessments (15). They subsequently completed a further
postal questionnaire and attended a follow-up assessment ap-
proximately 4 years later (range 3.0–5.7 y). Ethical approval for
the study was obtained in accordance with local institutional
requirements in each center. All subjects provided written in-
formed consent.
Assessments
The postal questionnaires included questions concerning cur-
rent smoking and current treatments for 14 medical conditions
(heart conditions; hypertension; diabetes; bronchitis; asthma;
peptic ulcer; epilepsy; liver, kidney and prostate conditions; and
pituitary, testicular, adrenal and thyroid diseases) or whether
they had ever been diagnosed with cancer or stroke. Participants
were asked also about their general health (response set: excel-
lent, very good, good, fair, poor) and completed the Beck’s De-
pression Inventory (BDI), a sexual function questionnaire (15)
and information on current medications was collected. Height
and body weight were measured in a standardized manner for
body mass index (BMI) calculation. Waist circumference was
measured at the midpoint between supra-iliac crest and lowest
rib to the nearest 0.1 cm.
Hormones and biochemistry
A single fasting morning (before 10:00 AM) venous blood
sample was obtained from each subject. T was measured by gas
chromatography-mass spectrometry as described previously
(16). SHBG was measured by the Modular E170 platform elec-
trochemiluminescence immunoassay (Roche Diagnostics). Free
T levels were derived from total T, SHBG, and albumin concen-
trations by the Vermeuelen formula (17).
Fasting total cholesterol, low-density lipoprotein (LDL) cho-
lesterol, high-density lipoprotein cholesterol, triglycerides, and
glucose were measured by standard methods (18). Insulin was
measured using chemiluminescence immunoassay (Siemens Im-
mulite 2000). Insulin resistance was calculated using the homeo-
static model (19).
Mortality
Deaths during the follow-up period were initially ascertained
either through contact by relatives on receipt of the postal ques-
tionnaire or, if this was not returned, by further inquiries to
ascertain the subject’s vital status. The enquiry procedure varied
between centers and included review of the medical records/
death registers and telephone follow-up. Deaths were verified
from death certificates (25%), death registers (37%), or medical/
hospital records (27%). Eleven percent of deaths were unverified
and information from the family member/contact person was the
only source. Deaths were categorized where possible as being due
to C (CVD), cancer, or other causes. Subjects who did not reply
to the follow-up postal questionnaire and for whom no further
information was available were classified as lost to follow-up.
Statistical analysis
LOH was defined as the presence of three sexual symptoms
(decreased frequency of morning erections and sexual thoughts
and erectile dysfunction) in combination with total T less than 11
nmol/L and free T less than 220 pmol/L (7). LOH was further
divided into two symptomatic subgroups: moderate, with total
T less than 11 and 8 nmol/L or greater and free T less than 220
pmol/L, and severe, with total T less than 8 nmol/L and free T less
than 220 pmol/L. Smoking status was categorized as current vs
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never and ex-smokers. Cardiovascular disease was defined as
subjects who reported having a stroke or were currently being
treated for heart conditions or hypertension. Comorbidity was
defined as a count of the number of medical conditions for which
a subject was currently being treated. Poor general health was
defined as poor/fair vs good/very good/excellent.
Kaplan-Meier methods were used to trace survival, and Cox
proportional hazard models were used to assess the risk of mor-
tality (all cause, CVD related, and cancer related were examined
separately). The following Cox proportional hazard models
were tested: 1) T and free T categorized into quintiles, with the
highest quintile as the reference group; 2) LOH status, with sub-
jects without LOH as the referent group; 3) low T irrespective of
sexual symptoms, with eugonadal as the referent group; 4) number
of sexual symptoms (0–3) irrespective of T levels, with 0 as the
referent group; and 5) each individual sexual symptom irrespective
ofTlevels.Theseanalyseswereperformedunadjusted(model I)and
then with serial adjustment for age and center (model II), BMI
(model III), and finally the remaining confounders found to be as-
sociated with both LOH status and mortality (model IV).
A stepwise Cox regression analysis was also performed.
Model A included only the confounders, model B added low T
with the eugonadal group as the reference category, model C
added the number of sexual symptoms (0–3, with 0 as the ref-
erence group) to model A, and finally, model D included low T,
number of sexual symptoms, and the confounders. The predic-
tive power of each of the models was compared using Harrell’s
C concordance statistic. An interaction term between low T and
sexual symptoms was fitted to model D to examine interactions.
Subanalyses were conducted excluding deaths in the first 12
months of follow-up, subjects with BMI greater than 30 kg/m2,
and subjects with diabetes. Results are reported as hazard ratios
(HRs) and 95% confidence intervals (CIs). For all models, the
assumption of proportional hazards was tested using the Schoe-
nfeld residuals. All statistical tests were performed using STATA
version 11.2 (http://www.stata.com).
Results
From the initial 3369 participants at baseline, 149 were
excluded because of known pituitary, testicular or adrenal
diseases, or current use of medications affecting pituitary/
testicular functions or clearance of sex steroids. Complete
Table 1. Baseline Characteristics of Subjects by Vital Status at End of the Follow-Up
Variable
Survived
(n  2452)
Mean (SD)
Died
(n  147) Pdiff Value
Age, y 58.9 (10.6) 69.3 (8.2) .001
Height, cm 174.1 (7.2) 170.0 (6.9) .001
Weight, kg 83.9 (13.7) 80 (16.9) .001
BMI, kg/m2 27.6 (4.0) 27.7 (5.1) NS
Waist circumference, cm 98.3 (10.8) 99.6 (12.6) NS
T, nmol/L 16.64 (5.9) 16.56 (6.3) NS
Free T, pmol/L 296.0 (86.3) 252.6 (88.1) .001
SHBG, nmol/L 42.0 (18.9) 53.3 (26.0) .001
Total cholesterol, mmol/L 5.6 (1.3) 5.4 (1.3) .05
HDL cholesterol, mmol/L 1.41 (0.37) 1.42 (0.44) NS
LDL cholesterol, mmol/L 3.5 (1.2) 3.3 (1.1) .05
Fasting glucose, mmol/L 5.6 (1.2) 6.2 (2.7) .001
Triglycerides, mmol/L 1.6 (1.2) 1.5 (0.8) NS
Insulin, pmol/L 11.9 (11.2) 13.1 (11.4) NS
HOMA-IR 3.2 (4.2) 3.7 (4.0) .09
BDI total score 6.4 (6.1) 11.2 (8.6) .001
%
Current smoker, yes vs no 20.1 29.9 .01
General heath, fair or poor 28.4 63.7 .001
Two or more morbid conditions 47.2 81.7 .001
CVD, yes vs no 33.6 59.9 .001
Diabetes, yes vs no 6.2 14.8 .001
Metabolic syndrome, yes vs no 21.6 27.2 NS
Cancer, yes vs no 4.5 15.0 .001
Infrequent sexual thoughts, yes vs no 24.1 54.4 .001
Morning erection, yes vs no 35.0 70.8 .001
Erectile dysfunction, yes vs no 26.7 66.7 .001
Number of sexual symptoms
0 47.6 17.0
1 28.3 16.3
2 14.9 24.5
3 9.3 42.2 .001
Abbreviation: HDL, high-density lipoprotein; HOMA-IR, homeostatic model for insulin resistance; ND, not determined. Pdiff used the t test,
Wilcoxon rank-sum, or 2 test as appropriate.
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baseline data on T and sexual symptoms were available
from 2966 men, among whom no information about vital
status could be obtained in 367 subjects (82 were too frail
or institutionalized and 285 lost to follow-up) leaving a
total of 2599 in this analysis. During a median of 4.3 years
of follow-up (range 3.0–5.7), comprising 11 140 person-
years, there were 147 deaths (overall mortality rate 5.7%),
of which 56 (38.1%) were due to CVD and 60 (40.8%) to
cancer. Six deaths were attributable to both CVD and
cancer. Of the remainder, 22 (15.0%) were due to other
causes and 15 (10.2%) had an unknown cause. Of the 55
men (2.1% of baseline cohort) classified as having LOH
(31 moderate and 24 severe), eight with moderate and nine
with severe LOH died. The baseline characteristics of sub-
jects who died by LOH status are presented in Supplemental
Table 1, published on The Endocrine Society’s Journals On-
line web site at http://jcem.endojournals.org. Mortality in
menwithLOHwashigher,30.9%(17of55), thanthatof the
entire cohort (5.7%). The distribution of causes of death in
subjectswithLOH(64.7%fromCVDand29.4%fromcan-
cer) was different from that in the whole cohort.
Table 1 shows the baseline demographic, clinical, and
biochemical characteristics of the entire analysis cohort
stratified by vital status at the end of the follow-up period.
There was no difference in total T levels between the
groups. However, those who died were older and had
lower free T and total and LDL cholesterol. They also had
higher SHBG, fasting glucose, and BDI total score. Among
those who died, a greater proportion smoked, were in
fair/poor general health, had at least two comorbid con-
ditions, CVD, diabetes, and cancer. Those who died were
also more likely to have one or more sexual symptoms.
Table 2. Influence of T and Free T (Categorized Into Quintiles) on Risk of All-Cause Mortality
Hazard Ratio (95% CI) for All-Cause Mortality
Model I Model II Model III Model IV
Quintiles of T, range in nmol/L
5, 21.20 Referent Referent Referent Referent
4, 17.28–21.20 1.1 (0.7, 1.8) 1.1 (0.7, 1.7) 1.1 (0.7, 1.8) 1.2 (0.7, 2.0)
3, 14.61–17.28 0.7 (0.4, 1.2) 0.7 (0.4, 1.2) 0.8 (0.4, 1.3) 0.7 (0.4, 1.3)
2, 11.65–14.61 0.7 (0.4, 1.2) 0.7 (0.4, 1.2) 0.7 (0.4, 1.3) 0.7 (0.4, 1.3)
1, 11.65 1.1 (0.7, 1.7) 1.0 (0.6, 1.6) 1.1 (0.6, 1.8) 1.1 (0.6, 1.8)
Quintiles of free T, range in pmol/L
5, 362.14 Referent Referent Referent Referent
4, 310.00–362.14 2.0 (1.0, 3.9)a 1.4 (0.7, 2.8) 1.3 (0.7, 2.7) 1.5 (0.8, 3.0)
3, 266.18–310.00 1.8 (0.9, 3.6) 1.0 (0.5, 2.0) 1.1 (0.5, 2.1) 1.0 (0.5, 2.1)
2, 224.86–266.18 2.1 (1.1, 4.1)a 0.9 (0.4, 1.7) 0.9 (0.5, 1.8) 0.9 (0.4, 1.8)
1, 224.86 4.2 (2.3, 7.7)b 1.4 (0.7, 2.7) 1.5 (0.8, 2.9) 1.3 (0.7, 2.6)
Model I is unadjusted; model II is adjusted for age and center; model III is adjusted for age, center, and BMI; and model IV is adjusted for age,
center, BMI, current smoking, and poor general health.
a P  .05.
b P  .001.
Table 3. Influence of T and Free T (Categorized Into Quintiles) on Risk of Cardiovascular-Related Mortality
Hazard Ratio (95% CI) for Cardiovascular-Related Mortality
Model I Model II Model III Model IV
Quintiles of T, range in nmol/L
5, 21.20 Referent Referent Referent Referent
4, 17.28–21.20 0.8 (0.4, 1.8) 0.8 (0.4, 1.8) 0.9 (0.4, 1.9) 1.1 (0.5, 2.4)
3, 14.61–17.28 0.4 (0.1, 1.0) 0.4 (0.2, 1.0) 0.4 (0.2, 1.1) 0.4 (0.2, 1.2)
2, 11.65–14.61 0.5 (0.2, 1.2) 0.5 (0.2, 1.3) 0.5 (0.2, 1.4) 0.5 (0.2, 1.4)
1, 11.65 1.0 (0.5, 2.2) 0.9 (0.4, 2.0) 0.9 (0.4, 2.1) 1.0 (0.4, 2.2)
Quintiles of free T, range in pmol/L 7
5, 362.14 Referent Referent Referent Referent
4, 310.00–362.14 1.2 (0.4, 4.0) 0.9 (0.3, 2.9) 0.7 (0.2, 2.5) 0.8 (0.2, 3.0)
3, 266.18–310.00 1.8 (0.6, 5.3) 0.9 (0.3, 2.7) 0.9 (0.3, 2.7) 1.0 (0.3, 2.9)
2, 224.86–266.18 2.1 (0.7, 6.1) 0.7 (0.2, 2.1) 0.7 (0.2, 2.1) 0.6 (0.2, 1.9)
1, 224.86 5.2 (2.0, 13.7)a 1.5 (0.5, 4.1) 1.4 (0.5, 4.1) 1.2 (0.4, 3.4)
Model I is unadjusted; model II is adjusted for age and center; model III is adjusted for age, center, and BMI; and model IV is adjusted for age,
center, BMI, current smoking, and poor general health.
a P  .01.
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There was no association between T (categorized into
quintiles) and all-cause or CVD-related mortality (Tables
2 and 3). The apparent association between free T and
mortality did not persist after adjustment for age and other
confounding factors. In contrast, there was a strong asso-
ciation between LOH and all-cause mortality with a pro-
gressive decline in the probability of survival over time
(Figure 1A). In unadjusted analyses, compared with men
without LOH, those with moderate and severe LOH had
nearly a 6- and a 10-fold higher risk of all-cause mortality,
respectively (Figure2A,model I).Adjustment forage,butnot
BMI or other potential confounders, attenuated this rela-
tionship, which remained statistically significant only for
subjects with severe LOH who had a 5-fold higher risk of
mortality (HR 5.5; 95% CI 2.7, 11.4) (Figure 2A, model IV).
In men with low T, irrespective of sexual symptoms, sim-
ilar although weaker relationships with mortality were ob-
served (Figures 1B and 2B and Table 4). Those with T less
than 8 nmol/L had a 2-fold higher risk. Adding low T to a
model containing the confounding factors improved the all-
cause mortality prediction slightly (C statistic 0.824 com-
pared with 0.817) (Table 4). The occurrence (number) of
sexual symptoms, irrespective of T levels, was associated
with a higher risk of all-cause mortality (Figures 1C and 2C
andTable4).Thosewith twoormoresexual symptomswere
at higher risk of mortality after adjustment for confounders
(Figure 2C and Table 4). Adding the number of sexual symp-
toms to a model containing the confounding factors im-
proved the mortality prediction (C statistic 0.837 compared
with 0.817; Table 4). Adding low T to this model improved
the prediction very slightly (C statistic 0.842 vs 0.837; Table
4). There was no statistically significant interaction between
low T and the number of sexual symptoms with respect to
all-cause mortality.
When the sexual symptoms were examined individually,
irrespectiveofT levels, all threewereassociatedwithahigher
risk of mortality: erectile dysfunction (HR 2.0, 95% CI 1.3,
2.9), poor morning erection (HR 2.1, 95% CI 1.4, 3.1),
and infrequent sexual thoughts (HR 1.6, 95% CI 1.1,
2.3) (Figure 2D).
Similar associations were observed between LOH sta-
tus and CVD-related mortality (Figure 3A). Compared
with men without LOH, those with moderate and severe
LOH had a 3-fold (HR 2.9, 95% CI 1.2, 7.1) and 8-fold
(HR 8.5, 95% CI 3.0, 23.8) higher risk of CVD mortality,
respectively, after adjustment for confounders. Those
with T less than 8 nmol/L, irrespective of sexual symp-
toms, had a higher risk of mortality compared with eu-
gonadal men (Figure 3B and Table 5). Compared with
those with no sexual symptoms, those with all three symp-
toms were at higher risk of CVD mortality after adjust-
ment for confounders (Figure 3C and Table 5). All three
sexual symptoms were significantly associated with CVD
mortality (Figure 3D).
A broadly similar pattern was observed with cancer
related mortality (Supplemental Table 2). Compared
Figure 1. Unadjusted Kaplan-Meier survival curves for LOH status (A),
low T irrespective of symptoms (B), and (C) number of sexual
symptoms.
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with those without LOH, men with severe LOH had a
5-fold higher risk of death from cancer. Those with T
less than 8 nmol/L, irrespective of symptoms, had a
3-fold higher risk compared with eugonadal men, and those
with all three symptoms, irrespective of T levels, had a 5-fold
higher riskofcancermortalitycomparedwithasymptomatic
men. Excluding subjects who reported diabetes at baseline,
those who died in the first year of follow-up or subjects with
BMI greater than 30 kg/m2 did not change the above results
(data not shown).
Figure 2. Cox proportional HR plots (95% CI) showing the influence on all-cause mortality of LOH status with eugonadal as the referent (A), low
T, irrespective of symptoms, with eugonadal as the referent (B), number of sexual symptoms (C), and individual sexual symptoms (D). Model I is
unadjusted; model II is adjusted for age and center; model III is adjusted for age, center, and BMI; and model IV is adjusted for age, center, BMI,
smoking, and poor general health. IST, infrequent sexual thoughts; PME, poor morning erection.
Table 4. Influence of Low T and Number of Sexual Symptoms on Risk of All-Cause Mortality
Hazard Ratio (95% CI) for All-Cause Mortality
Model A Model B Model C Model D
Low T
Eugonadal Referent Referent
T 8–11 nmol/l 1.0 (0.6, 1.8) 1.0 (0.6, 1.8)
T 8 nmol/l 2.3 (1.2, 4.2)a 2.2 (1.2, 4.1)a
No of sexual symptoms
0 Referent Referent
1 1.1 (0.6, 2.0) 1.1 (0.6, 2.0)
2 1.8 (1.0, 3.3)a 1.8 (1.0, 3.2)a
3 3.2 (1.8, 5.8)b 3.1 (1.7, 5.7)b
C statistic for model 0.817 0.824 0.837 0.842
Model A included age, center, BMI, current smoking, and poor general health. Model B included low T, age, center, BMI, current smoking, and
poor general health. Model C included number of sexual symptoms, age, center, BMI, current smoking, and poor general health. Model D
included low T, number of sexual symptoms, age, center, BMI, current smoking, and poor general health.
a P  .05.
b P  .001
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Discussion
In this population-based sample of middle-aged and older
men, severe LOH was associated with a 5-fold higher risk of
all-cause mortality after adjustment for confounders. The
excess risk appeared to be a combination of low T (8
nmol/L) and the presence of all three sexual symptoms,
which were independently associated with a 2- and 3-fold
higher all-cause mortality, respectively. There was no inter-
action between low T and sexual symptoms with respect to
mortality risks.LOHwasalso stronglyassociatedwithCVD
and cancer-related mortality.
Figure 3. Cox proportional HR plots (95% CI) showing the influence on cardiovascular-related mortality of LOH status, with eugonadal as the
referent (A); low T irrespective of symptoms, with eugonadal as the referent (B); number of sexual symptoms (C); and individual sexual symptoms
(D). Model I is unadjusted; model II is adjusted for age and center; model III is adjusted for age, center, and BMI; and model IV is adjusted for age,
center, BMI, smoking, and poor general health. IST, infrequent sexual thoughts; PME, poor morning erection.
Table 5. Influence of Low T and Number of Sexual Symptoms on Risk of Cardiovascular-Related Mortality
Hazard Ratio (95% CI) for Cardiovascular-Related Mortality
Model A Model B Model C Model D
Low T
Eugonadal Referent Referent
T 8–11 nmol/l 1.2 (0.5, 2.8) 1.2 (0.5, 2.7)
T 8 nmol/l 2.8 (1.1, 7.0)a 3.1 (1.2, 7.6)a
No of sexual symptoms
0 Referent Referent
1 0.9 (0.3, 2.8) 0.8 (0.3, 2.7)
2 2.2 (0.8, 6.2) 2.1 (0.7, 6.0)
3 3.8 (1.3, 10.9)a 3.8 (1.3, 10.8)a
C statistic for model 0.873 0.884 0.895 0.902
Model A included age, center, BMI, current smoking and poor general health. Model B included low T, age, center, BMI, current smoking and
poor general health. Model C included number of sexual symptoms, age, center, BMI, current smoking and poor general health. Model D included
low T, number of sexual symptoms, age, center, BMI, current smoking and poor general health.
a P  .05.
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The association between endogenous total T and/or
free T and all-cause mortality in men has been observed in
some (20–27) but not all studies (28–31). A recent sys-
tematic review and meta-analysis of 12 community based
studies, 11 of which included data on all-cause mortality,
concluded that low total T was linked to a higher risk of
all-cause and CVD mortality, but there was considerable
between-study heterogeneity in results, attributable to dif-
ferences in subject characteristics (including age, baseline
T, and length of follow-up) (9). In our study, mean T levels
were similar between men who died and survivors, and
even when total T was categorized into quintiles, we found
no association with mortality (Table 2). Similar to other
studies (10, 27), our results showed that free T was asso-
ciated with mortality; however, this did not persist after
adjustment, suggesting that the relationship was con-
founded by increasing age. Our observation of a 2-fold
increase in risk of mortality only in men with total T less
than 8 nmol/L suggests a nonlinear relationship that
emerges only when T has declined into the unequivocally
hypogonadal range (4, 5).
The association between T deficiency and an increased
risk of cardiovascular mortality has been observed in some
(21, 22, 26, 27, 29), although not all (24, 25, 28), studies.
A meta-analysis of seven population-based studies con-
cluded that there was a borderline significant link between
endogenous T and death from a cardiovascular cause (9),
in keeping with our findings. The relationships between
androgens and cardiovascular disease are complex and
inconsistent (32–34). In our analysis, we did not adjust a
priori for prevalent CVD on the basis that it could act as
a path variable, ie, low T could have a negative influence
on the cardiovascular system leading to CVD, which in
turn leads to all-cause/CVD-related death. However, a
post hoc analysis adjusting for prevalent CVD in the final
multivariate models made no difference to the observed
mortality risks (data not shown). This would imply that
the relationship between low T and increased mortality
was not mediated through a direct effect on the cardio-
vascular system. Thus, whether low T mediates a causal
link or represents a marker of poor cardiometabolic health
remains uncertain (10, 34).
Our observation of a link between LOH and mortality
was not, however, specific to cardiovascular disease. We
also found a strong association with cancer-related mor-
tality. This observation is in keeping with some (21, 26)
but not all studies (22, 29), further raising the possibility
of reverse causality.
ED and CVD frequently coexist and share many risk
factors (35). There is increasing evidence to suggest that
ED is an independent marker of increased CVD risk and
mortality (12–14). It has also been suggested that ED may
be a sentinel symptom of cardiovascular disease (13), pre-
ceding coronary events by 2–5 years (36). Our observation
of an association between sexual symptoms and CVD
mortality is compatible with this. However, our finding
that sexual symptoms are also associated with all-cause
mortality may indicate that the presence of these symp-
toms is a marker or consequence of chronic comorbid
diseases and general ill health. Erectile/sexual dysfunction
and low T frequently coexist in a significant subgroup of
men (7). It is therefore interesting to note that the present
results showed no interaction between low T and sexual
symptoms with regard to mortality, suggesting that the
associations are independent and may be additive, al-
though the relatively small number of deaths observed in
this study may have precluded detection of such
interactions.
The pathophysiological basis of the present findings
remains unclear. It is not possible to differentiate whether
low T/LOH is the cause or mediator of higher mortality or
merely a nonspecific marker of, or specific adaptive re-
sponse to, poor health. Although there was only a small
number of men with severe LOH in this study, nonethe-
less, the association with multiple causes of mortality
makes it less likely that T deficiency per se is the sole ex-
planation, whereas erectile/sexual symptoms (surrogate
for poor vascular health) may be even more important
than low T. Taken together, the present data suggest that
LOH represents a marker of poor health in aging, albeit
that a bidirectional relationship cannot be excluded.
These considerations have important implications on our
approach to clinical management and the rationale for T
replacement in symptomatic older men with low T. Al-
though a recent retrospective observational study re-
ported a lower mortality in T-treated compared with un-
treated veterans (37), it cannot be concluded that the T
treatment actually reduced mortality (38). The clinical im-
plication of the present findings is that sexual dysfunction
and low T, which often coexist as LOH, should be recog-
nized as an important window of opportunity for improv-
ing aging men’s general health and survival and subse-
quent assessment and reduction of adverse health
(especially cardiometabolic risk) factors.
Our observation that BMI (or waist circumference;
data not shown) did not attenuate the association between
LOH and mortality is noteworthy; it confirms other stud-
ies that the higher risk of all-cause and CVD death asso-
ciated with low T was independent of BMI (9, 21). Obesity
is an established CVD risk factor and we (and others) have
shown that low T is strongly associated with overall or
central obesity (17). This raises the possibility that the
quality or function may be more important than the quan-
tity of fatty tissue as a risk mediator for CVD. There is also
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evidence from population-based studies that BMI has a
J-shaped relationship with mortality (39). This could be an
alternative explanation for the lack of attenuation when
adjusting for BMI in our statistical models.
The main strengths of our study include the prospec-
tive, population-based data with detailed phenotyping of
men (including documentation of sexual symptoms with a
validated questionnaire) stringently identified to be likely
candidates for hypogonadism using standardized assess-
ment and state-of-the-art gas chromatography mass spec-
trometry measurement of T. Methodological limitations
inherent to the EMAS study have been described in detail
previously (15), as have limitations pertaining to the use of
a single, as opposed to repeated, T measurement and the
calculation, rather than the direct measurement, of free T
(17). In our study the overall loss to follow-up rate was
9.9% (40). Compared with participants, those lost to fol-
low-up had lower 25-hydroxyvitamin D levels (mean 55.2
vs 64.4 nmol/L), lower physical functioning as measured
by Reuben’s physical performance test rating (mean 23.8
vs 24.2) and a lower mental processing speed as measured
by digit symbol substitution score (mean 26.0 vs 28.5) and
consequently may be at increased risk of mortality (40).
Our findings concerning mortality among the participants
may therefore underestimate the true mortality experience
of the full cohort. Compared with participants, those lost
to follow-up (n367) had similar total T levels at baseline
[mean (SD) 16.6 (5.9) vs 16.3 (6.0), respectively]. Fur-
thermore, because no systematic differences were ob-
served between participants and those lost to follow-up in
relation to LOH status, the losses to follow-up are unlikely
to have influenced the main findings. The loss to follow-up
rate varied across the participating centers (4.4%–
16.3%); however, adjusting for the effect of center in the
analysis did not alter the main findings. Sixteen percent of
the information on CVD-related deaths and 7% of the
information on cancer-related deaths came from family
members or a contact person of the deceased; hence, these
data should be interpreted with caution. However, exclu-
sion of these unverified deaths made no difference to the
results (data not shown).
In summary, LOH, as defined by the presence of three
sexual symptoms and low T, was associated with a sub-
stantial increased risk of all-cause, CVD, and cancer mor-
tality. The excess mortality risk was less marked in men
with low T only, underlying the importance of sexual
symptoms in the diagnosis and outcome of LOH. Eliciting
sexual symptoms and documenting low T offers an im-
portant opportunity to identify a small subgroup of men
at particularly high risk of dying.
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